Melatonin and its analogs in insomnia and depression

Journal of Pineal Research

Volumn 52, Issue 4, 2012, Pages 365-375

  Cardinali, Daniel P ^a   Srinivasan, Venkataramanujan ^b   Brzezinski, Amnon ^c   Brown, Gregory M ^d,e  

^a PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

^b Sri Sathya Sai Medical Educational and Research Foundation   (India)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d UNIVERSITY OF TORONTO   (Canada)

^e CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

agomelatine; circadin; depression; insomnia; melatonin; ramelteon; tasimelteon; TIK 301

Indexed keywords

4 AMINOBUTYRIC ACID; 6 HYDROXYMELATONIN O SULFATE; AGOMELATINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; DRUG METABOLITE; ESZOPICLONE; HYPNOTIC AGENT; MELATONIN; MELATONIN DERIVATIVE; RAMELTEON; SEROTONIN 2C ANTAGONIST; TASIMELTEON; TIK 301; UNCLASSIFIED DRUG; VENLAFAXINE; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ANTIDEPRESSANT ACTIVITY; BINDING AFFINITY; CLINICAL TRIAL (TOPIC); DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DROWSINESS; DRUG BINDING; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HALF LIFE TIME; HEADCAHE; HUMAN; IC 50; INSOMNIA; MEMORY DISORDER; META ANALYSIS (TOPIC); NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROGRADE AMNESIA; REVIEW;

ACETAMIDES; ANIMALS; DEPRESSION; HUMANS; HYPNOTICS AND SEDATIVES; INDENES; MELATONIN; MICE; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84859727234     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2011.00962.x     Document Type: Review

References (129)

1. Brzezinski A,. Melatonin in humans. N Engl J Med 1997; 336: 186-195.
2. Zee PC, Manthena P,. The brain's master circadian clock: implications and opportunities for therapy of sleep disorders. Sleep Med Rev 2007; 11: 59-70.
3. Haimov I, Laudon M, Zisapel N, et al., Sleep disorders and melatonin rhythms in elderly people. BMJ 1994; 309: 167.
4. Hughes RJ, Badia P,. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep 1997; 20: 124-131.
5. Leger D, Laudon M, Zisapel N,. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004; 116: 91-95.
6. Cajochen C, Jewett ME, Dijk DJ,. Human circadian melatonin rhythm phase delay during a fixed sleep-wake schedule interspersed with nights of sleep deprivation. J Pineal Res 2003; 35: 149-157.
7. Lavie P,. Melatonin: role in gating nocturnal rise in sleep propensity. J Biol Rhythms 1997; 12: 657-665.
8. Zhdanova IV, Wurtman RJ, Regan MM, et al., Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001; 86: 4727-4730.
9. Wilson SJ, Nutt DJ, Alford C, et al., British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010; 24: 1577-1601.
10. Arendt J, Skene DJ, Middleton B, Lockley SW, Deacon S,. Efficacy of melatonin treatment in jet lag, shift work, and blindness. J Biol Rhythms 1997; 12: 604-617.
11. Pandi-Perumal SR, Trakht I, Spence DW, Srinivasan V, Dagan Y, Cardinali DP,. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders. Nat Clin Pract Neurol 2008; 4: 436-447.
12. Srinivasan V, Singh J, Pandi-Perumal SR, et al., Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs. Adv Ther 2010; 27: 796-813.
13. Reppert SM, Weaver DR, Ebisawa T,. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994; 13: 1177-1185.
14. Dubocovich ML, Delagrange P, Krause DN, et al., International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010; 62: 343-380.
15. Turek FW, Gillette MU,. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004; 5: 523-532.
16. Most EI, Scheltens P, Van Someren EJ,. Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light-a randomized clinical trial. Trials 2010; 11: 19.
17. Van Someren EJ,. Circadian and sleep disturbances in the elderly. Exp Gerontol 2000; 35: 1229-1237.
18. Summers MO, Crisostomo MI, Stepanski EJ,. Recent developments in the classification, evaluation, and treatment of insomnia. Chest 2006; 130: 276-286.
19. Cricco M, Simonsick EM, Foley DJ,. The impact of insomnia on cognitive functioning in older adults. J Am Geriatr Soc 2001; 49: 1185-1189.
20. Vgontzas AN, Kales A,. Sleep and its disorders. Annu Rev Med 1999; 50: 387-400.
21. Bastien CH,. Insomnia: neurophysiological and neuropsychological approaches. Neuropsychol Rev 2011; 21: 22-40.
22. Drake CL, Roehrs T, Richardson G, Walsh JK, Roth T,. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep 2004; 27: 1453-1462.
23. Montgomery P, Dennis J,. A systematic review of non-pharmacological therapies for sleep problems in later life. Sleep Med Rev 2004; 8: 47-62.
24. Mandrioli R, Mercolini L, Raggi MA,. Metabolism of benzodiazepine and non-benzodiazepine anxiolytic-hypnotic drugs: an analytical point of view. Curr Drug Metab 2010; 11: 815-829.
25. A receptors. Curr Top Med Chem 2011; 11: 241-246.
26. Nowell PD, Mazumdar S, Buysse DJ, et al., Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997; 278: 2170-2177.
27. Morin AK,. Strategies for treating chronic insomnia. Am J Manag Care 2006; 12: S230-S245.
28. Cardinali DP, Pandi-Perumal SR, Srinivasan V, Spence DW, Trakht I,. Therapeutic potential of melatonin agonists. Exp Rev Endocrinol Metab 2008; 3: 269-279.
29. A receptor subtypes. Eur J Pharmacol 2002; 451: 103-110.
30. Morin AK, Willett K,. The role of eszopiclone in the treatment of insomnia. Adv Ther 2009; 26: 500-518.
31. Rosenberg RP,. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry 2006; 18: 49-56.
32. Ramakrishnan K, Scheid DC,. Treatment options for insomnia. Am Fam Physician 2007; 76: 517-526.
33. Ancoli-Israel S, Richardson GS, Mangano RM, et al., Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005; 6: 107-113.
34. Morera AL, Abreu-Gonzalez P, Henry M,. Zaleplon increases nocturnal melatonin secretion in humans. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1013-1016.
35. Montplaisir J, Hawa R, Moller H, et al., Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol 2003; 18: 29-38.
36. Krystal AD, Walsh JK, Laska E, et al., Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003; 26: 793-799.
37. Hair PI, Mccormack PL, Curran MP,. Eszopiclone: a review of its use in the treatment of insomnia. Drugs 2008; 68: 1415-1434.
38. Zammit GK, Mcnabb LJ, Caron J, Amato DA, Roth T,. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004; 20: 1979-1991.
39. Zammit G,. Comparative tolerability of newer agents for insomnia. Drug Saf 2009; 32: 735-748.
40. Wilson AJ, Carati CJ, Gannon BJ, Haberberger R, Chataway TK,. Aquaporin-1 in blood vessels of rat circumventricular organs. Cell Tissue Res 2010; 340: 159-168.
41. Roth T, Krystal AD, Lieberman JA III,. Long-term issues in the treatment of sleep disorders. CNS Spectr 2007; 12: 1-13.
42. Mendelson WB,. Melatonin microinjection into the medial preoptic area increases sleep in the rat. Life Sci 2002; 71: 2067-2070.
43. Cardinali DP, Golombek DA,. The rhythmic GABAergic system. Neurochem Res 1998; 23: 607-614.
44. Golombek DA, Pevet P, Cardinali DP,. Melatonin effect on behavior: possible mediation by the central GABAergic system. Neurosci Biobehav Rev 1996; 20: 403-412.
45. Inyushkin AN, Bhumbra GS, Gonzalez JA, Dyball RE,. Melatonin modulates spike coding in the rat suprachiasmatic nucleus. J Neuroendocrinol 2007; 19: 671-681.
46. Liu C, Weaver DR, Jin X, et al., Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997; 19: 91-102.
47. Jan JE, Reiter RJ, Wong PK, et al., Melatonin has membrane receptor-independent hypnotic action on neurons: an hypothesis. J Pineal Res 2011; 50: 233-240.
48. Dollins AB, Zhdanova IV, Wurtman RJ, Lynch HJ, Deng MH,. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci U S A 1994; 91: 1824-1828.
49. Garfinkel D, Laudon M, Nof D, Zisapel N,. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995; 346: 541-544.
50. Zhdanova IV, Wurtman RJ, Lynch HJ, et al., Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 1995; 57: 552-558.
51. Zhdanova IV, Wurtman RJ, Morabito C, Piotrovska VR, Lynch HJ,. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 1996; 19: 423-431.
52. Monti JM, Alvarino F, Cardinali D, Savio I, Pintos A,. Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia. Arch Gerontol Geriatr 1999; 28: 85-98.
53. Buscemi N, Vandermeer B, Hooton N, et al., Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006; 332: 385-393.
54. Brzezinski A, Vangel MG, Wurtman RJ, et al., Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9: 41-50.
55. Gorfine T, Assaf Y, Goshen-Gottstein Y, Yeshurun Y, Zisapel N,. Sleep-anticipating effects of melatonin in the human brain. Neuroimage 2006; 31: 410-418.
56. Mendelson WB,. A critical evaluation of the hypnotic efficacy of melatonin. Sleep 1997; 20: 916-919.
57. Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM,. Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci 2000; 25: 48-52.
58. Lemoine P, Guilleminault C, Alvarez E,. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723-1732.
59. Lemoine P, Nir T, Laudon M, Zisapel N,. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007; 16: 372-380.
60. Wade AG, Crawford G, Ford I, et al., Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin 2011; 27: 87-98.
61. 2 receptor agonist. Neuropharmacology 2005; 48: 301-310.
62. 2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther 2009; 15: 32-51.
63. Cajochen C,. TAK-375 Takeda. Curr Opin Investig Drugs 2005; 6: 114-121.
64. 2. J Clin Pharmacol 2007; 47: 485-496.
65. Stevenson S, Bryson S, Amayke D, Hibberd M,. Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects. Clin Pharmacol Ther 2004; 75: P22.
66. 1 with vasopressin, oxytocin, and corticotropin-releasing hormone. J Comp Neurol 2006; 499: 897-910.
67. 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J Pineal Res 2002; 32: 59-62.
68. 2 melatonin receptor expression in Alzheimer's disease. J Pineal Res 2005; 38: 10-16.
69. 2 melatonin receptor subtype is present in human retina and decreases in Alzheimer's disease. Curr Alzheimer Res 2007; 4: 47-51.
70. 2 are decreased in Alzheimer's disease. Eur J Histochem 2006; 50: 311-316.
71. Yukuhiro N, Kimura H, Nishikawa H, et al., Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res 2004; 1027: 59-66.
72. France CP, Weltman RH, Koek W, Cruz CM, Mcmahon LR,. Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta): dependence liability studies. Behav Neurosci 2006; 120: 535-541.
73. Saper CB, Lu J, Chou TC, Gooley J,. The hypothalamic integrator for circadian rhythms. Trends Neurosci 2005; 28: 152-157.
74. Saper CB, Scammell TE, Lu J,. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005; 437: 1257-1263.
75. Kalsbeek A, Perreau-Lenz S, Buijs RM,. A network of (autonomic) clock outputs. Chronobiol Int 2006; 23: 521-535.
76. Reghunandanan V, Reghunandanan R,. Neurotransmitters of the suprachiasmatic nuclei. J Circadian Rhythms 2006; 4: 2.
77. Pandi-Perumal SR, Srinivasan V, Spence DW, et al., Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther 2009; 26: 613-626.
78. Srinivasan V, Pandi-Perumal SR, Trahkt I, et al., Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci 2009; 119: 821-846.
79. Roth T, Seiden D, Sainati S, et al., Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006; 7: 312-318.
80. Erman M, Seiden D, Zammit G, Sainati S, Zhang J,. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006; 7: 17-24.
81. Roth T, Seiden D, Wang-Weigand S, Zhang J,. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007; 23: 1005-1014.
82. Zammit G, Erman M, Wang-Weigand S, et al., Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007; 3: 495-504.
83. Mini L, Wang-Weigand S, Zhang J,. Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect. Clin Ther 2008; 30: 1316-1323.
84. Dobkin RD, Menza M, Bienfait KL, et al., Ramelteon for the treatment of insomnia in menopausal women. Menopause Int 2009; 15: 13-18.
85. Mayer G, Wang-Weigand S, Roth-Schechter B, et al., Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009; 32: 351-360.
86. Uchimura N, Ogawa A, Hamamura M, et al., Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a randomized, double-blind, placebo-controlled study. Expert Rev Neurother 2011; 11: 215-224.
87. Uchiyama M, Hamamura M, Kuwano T, et al., Long-term safety and efficacy of ramelteon in Japanese patients with chronic insomnia. Sleep Med 2011; 12: 127-133.
88. Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP,. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat Clin Pract Neurol 2007; 3: 221-228.
89. Richardson GS, Zee PC, Wang-Weigand S, Rodriguez L, Peng X,. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J Clin Sleep Med 2008; 4: 456-461.
90. Lam RW,. Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol 2006; 21 (Suppl 1): S25-S29.
91. Kupfer DJ,. Depression and associated sleep disturbances: patient benefits with agomelatine. Eur Neuropsychopharmacol 2006; 16 (Suppl 5): S639-S643.
92. 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954-964.
93. Bourin M, Mocaer E, Porsolt R,. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004; 29: 126-133.
94. Bertaina-Anglade V, La Rochelle CD, Boyer PA, Mocaer E,. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol 2006; 17: 703-713.
95. Fuchs E, Simon M, Schmelting B,. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int Clin Psychopharmacol 2006; 21 (Suppl 1): S17-S20.
96. Millan MJ,. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110: 135-370.
97. 2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci 2009; 29: 1795-1809.
98. 2C receptors acutely induces Per1 gene expression in the rat SCN in vitro. Brain Res 2008; 1209: 19-28.
99. Martin JR, Bos M, Jenck F, et al., 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 1998; 286: 913-924.
100. Detanico BC, Piato AL, Freitas JJ, et al., Antidepressant-like effects of melatonin in the mouse chronic mild stress model. Eur J Pharmacol 2009; 607: 121-125.
101. Mcelroy SL, Winstanley EL, Martens B, et al., A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. Int Clin Psychopharmacol 2010; 26: 48-53.
102. Crupi R, Mazzon E, Marino A, et al., Melatonin treatment mimics the antidepressant action in chronic corticosterone-treated mice. J Pineal Res 2010; 49: 123-129.
103. De Bodinat C, Guardiola-Lemaitre B, Mocaer E, et al., Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010; 9: 628-642.
104. Srinivasan V, Cardinali DP, Pandi-Perumal SR, Brown GM,. Melatonin agonists for treatment of sleep and depressive disorders. J Exp Integrat Med 2011; 1: 149-158.
105. 2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239-247.
106. Kennedy SH, Emsley R,. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 93-100.
107. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C,. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2007; 9: 628-635.
108. Llorca PM,. The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission. J Psychopharmacol 2010; 24: 21-26.
109. Di Giannantonio M, Di Iorio G, Guglielmo R, et al., Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents 2011; 25: 109-114.
110. Eser D, Baghai TC, Moller HJ,. Agomelatine: the evidence for its place in the treatment of depression. Core Evid 2010; 4: 171-179.
111. Srinivasan V, Brzezinski A, Spence DW, et al., Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment. Psychiatria Fennica 2010; 41: 168-187.
112. De Berardis D, Di Iorio G, Acciavatti T, et al., The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets 2011; 10: 119-132.
113. Armitage R,. Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand Suppl 2007; 433: 104-115.
114. Ford DE, Kamerow DB,. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?. JAMA 1989; 262: 1479-1484.
115. Lustberg L, Reynolds CF,. Depression and insomnia: questions of cause and effect. Sleep Med Rev 2000; 4: 253-262.
116. Quera Salva MA, Vanier B, Laredo J, et al., Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007; 10: 691-696.
117. Zupancic M, Guilleminault C,. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006; 20: 981-992.
118. Lopes MC, Quera-Salva MA, Guilleminault C,. Cycling alternating pattern in the NREM sleep of patients within major depressive disorder: baseline results and change overtime with a new antidepressant. Sleep Med 2005; 6 (Suppl 2): 87-88.
119. Lopes MC, Quera-Salva MA, Guilleminault C,. Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine). Sleep Med 2007; 9: 33-41.
120. Hardeland R, Poeggeler B, Srinivasan V, et al., Melatonergic drugs in clinical practice. Arzneimittelforschung 2008; 58: 1-10.
121. Kasper S, Hajak G, Wulff K, et al., Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010; 71: 109-120.
122. Vachharajani NN, Yeleswaram K, Boulton DW,. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J Pharm Sci 2003; 92: 760-772.
123. Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al., Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009; 373: 482-491.
124. Lankford DA,. Tasimelteon for insomnia. Expert Opin Investig Drugs 2011; 20: 987-993.
125. Mulchahey JJ, Goldwater DR, Zemlan FP,. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. Life Sci 2004; 75: 1843-1856.
126. Zemlan FP, Mulchahey JJ, Scharf MB, et al., The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 2005; 66: 384-390.
127. Hardeland R, Cardinali DP, Srinivasan V, et al., Melatonin-a pleiotropic, orchestrating regulator molecule. Prog Neurobiol 2011; 93: 350-384.
128. Kennedy SH, Rizvi SJ,. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010; 24: 479-499.
129. Weishaupt JH, Bartels C, Polking E, et al., Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006; 41: 313-323.